top of page

The Co-CEO of Renibus Therapeutics shares a company's perspective of the N. Texas biotech ecosystem

  • blonca9
  • Oct 25, 2023
  • 1 min read

Updated: Oct 26, 2023

Jeff Keyser tells us about trying to help patients recover from surgeries more efficiently and the phase 2 data that led to Renibus' breakthrough therapy designation.



Brought to you by:



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page